Status:
COMPLETED
A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease
Lead Sponsor:
Genentech, Inc.
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50-86 years
Phase:
PHASE1
Brief Summary
This is a Phase I, multicenter, randomized, double-blind, placebo-controlled study that will be conducted in the United States and consists of a single ascending-dose stage followed by a multidose, pa...
Eligibility Criteria
Inclusion
- Diagnosis of probable AD according to the NINCDS-ADRDA Criteria
- Approved AD treatments (AchE inhibitors+/-memantine) must be stable for ≥ 3 months prior to screening
- Other prescription medications must be stable for ≥ 1 month prior to screening
Exclusion
- Female patients with reproductive potential
- History or presence of any clinically significant CNS disease
- History of treatment with any protein therapeutic targeting Abeta
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00736775
Start Date
August 1 2008
Last Update
October 27 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.